Deutsche Bank raised the firm’s price target on Genmab (GMAB) to DKK 2,000 from DKK 1,900 and keeps a Buy rating on the shares.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GMAB:
- Genmab price target raised to $49 from $46 at Truist
- Genmab price target raised to $40 from $36 at H.C. Wainwright
- Genmab A/S Updates Articles of Association to Enhance Growth Strategy
- Genmab’s Strategic Acquisitions and Promising Pipeline Drive Buy Rating
- Genmab’s Strategic Acquisition of MRUS: A Long-Term Positive Move Enhancing Pipeline and Growth Potential